DURHAM, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its underwritten public offering of 14,375,000 shares of common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof), including full exercise of the underwriter's overallotment option. Each share of common stock (or Pre-Funded Warrant) was offered at a publi ...

DURHAM, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the new pricing of an underwritten public offering of 12,500,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being offered at a public offering price of $1.00 per share (inclusive of the Pre-Funde ...

DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced a delay in its previously announced public offering. The Company has requested, and the NYSE has approved, a financial viability exception to the NYSE American shareholder approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to p ...

Scorpius (NYSEMKT:SCPX) stock is taking a beating on Wednesday after the company provided details on a public offering. Scorpius has announced that it will sell 12.5 million shares of SCPX stock in this public offering. The company has also priced these shares at $1 each. That will see it generate gross proceeds of $125 million from this offering. Additionally, underwriters have a 45-day option to acquire another 1.875 million shares of SCPX stock at the offering price. This could provide the company with a ...

Form 8-K Current Report [Item 2.02. Results of Operations and Financial Condition](index=1&type=section&id=Item%202.02.%20Results%20of%20Operations%20and%20Financial%20Condition) Scorpius Holdings, Inc. announced preliminary unaudited Q2 2024 financial results, projecting revenue between **$0.3 million and $0.8 million** and an operating loss of **$8.6 million to $9.1 million**, with larger cGMP manufacturing contracts expected to contribute to revenue starting Q3 2024 Preliminary Unaudited Financial Estimates for Q2 2024 | Financial Metric | Estimated Range (in millions) | | :--- | :--- | | Revenue | $0.3 - $0.8 | | Operating Loss | $8.6 - $9.1 | | Net Loss Before Income Taxes (from continuing operations) | $9.2 - $9.7 | - As of June 30, 2024, the company's cash, cash equivalents, and short-term investments were approximately **$1.5 million**[3](index=3&type=chunk) - Revenue for the first six months of 2024 was primarily from process development work, with anticipated revenue generation from microbial cGMP manufacturing, which began in July 2024, and mammalian cGMP manufacturing, expected to start in Q3 2024, with these manufacturing contracts projected to be larger than current process development contracts[3](index=3&type=chunk) - The provided financial estimates are preliminary, based on currently available information, and are subject to adjustments upon completion of the company's financial closing procedures, and have not been audited or reviewed by the company's independent registered public accounting firm[4](index=4&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section details the exhibits filed as part of the Form 8-K report - Exhibit 104, the Cover Page Interactive Data File, was filed with this report[2](index=2&type=chunk)[5](index=5&type=chunk)

As filed with the Securities and Exchange Commission on July 31, 2024. Registration Number 333-280887 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SCORPIUS HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 26-2844103 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification N ...

Scorpius Holdings, Inc. Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purposebuilt U.S. facilities, Scorpius is dedicated to transparen ...

Scorpius has previously initiated cGMP activities in its microbial facilities, and the commencement of mammalian cGMP campaigns marks a significant development as it opens additional revenue streams for the Company's CDMO operations. Scorpius boasts a dedicated mammalian cell culture facility with cGMPcompliant controlled cleanrooms illustrating Scorpius' commitment to providing tailored and adaptable manufacturing solutions. Scorpius Holdings Inc. is an integrated contract development and manufacturing org ...

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius' support for manufacturing programs through clinical manufacturing, with aspirations for future ...

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius' support for manufacturing programs through clinical manufacturing, with aspirations for future ...